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We have recently completed a 200-page report entitled ‘A
Systematic Review of the Role of Human Papilloma Virus (HPV)
Testing within a Cervical Screening Programme’ (Cuzick et al,
1999b) for the Health Technology Assessment Committee of the
British Department of Health. As this document is not easily avail-
able, here we report the main results of that review including the
conclusions and recommendations.
There is little doubt that well-organized cytology-based
screening programmes for cervical cancer have been effective in
reducing cancer incidence and preventing premature deaths. This is
especially true of those that have good quality assurance. Potential
reductions in disease of 60–90% are possible in the three years after
screening (IARC, 1986; Sasieni et al, 1996). The importance of
good coverage and quality control is demonstrated by the acceler-
ated decline in mortality in England and Wales following the
changes implemented in 1988 (Sasieni et al, 1995), addressing
problems identified in the early 1980s (ICRF, 1984, 1986).
However, a recent audit (Sasieni et al, 1996) found that 47% of
fully invasive cancers in women under the age of 70 occurred
despite an apparently adequate screening history, suggesting prob-
lems with the sensitivity of the test. Further progress in reducing
the disease burden is therefore likely to come from a combination
of measures to extend the coverage of screening, and more accu-
rately identify women with precursor lesions.
The sensitivity of cytology is limited by sampling error, in
which the abnormal cells do not get placed on the smear, and
reading error, where a few abnormal cells are not identified among
the multitude of normal cells that are also present in a well-taken
cervical smear. Sensitivities for cytology of only 40–80% for high-
grade cervical intraepithelial neoplasia (CIN II/III) have been
reported (Reid et al, 1991; Cox et al, 1995; Cuzick et al, 1995).
Furthermore, cytologic screening is poor at detecting glandular
lesions or adenocarcinoma, which account for a growing number
of cervical cancers (Kjaer and Brinton, 1993; Vizcaino, et al,
1998). Cytology also has problems with specificity, and the
screening programme is overburdened by borderline and mildly
dyskaryotic smears, which are costly to follow-up, cause anxiety
to the women concerned, but have low predictive value for high-
grade pathology (Shafi, 1994; Raffle et al, 1995).
The causal association between infection with certain HPV
types and the development of cervical cancer is now beyond
reasonable dispute. The epidemiological data supporting this
assertion include reports that HPV DNA can be recovered from
over 95% of all cervical tumours (Bosch et al, 1995; Walboomers
et al, 1999; Cuzick et al, 2000), and that women infected with
oncogenic HPV types have relative risks of 40–180 for the devel-
opment of high-grade cervical disease (IARC, 1995; Olsen et al,
1995). Additionally, molecular studies have identified mecha-
nisms by which high-risk HPV types contribute to carcinogenesis.
The World Health Organization and the International Agency for
Research on Cancer have officially designated HPVs 16 and 18 as
carcinogenic agents. Even higher relative risks (100–500) are
reported for persistent HPV infection, which appears to be the key
step in cervical carcinogenesis (Nobbenhuis et al, 1999).
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doi: 10.1054/ bjoc.2000.1375, available online at http://www.idealibrary.com on A plateau of what can be achieved by conventional cytology is
now being reached, and the fundamental importance of HPV in the
aetiology of cervical cancer has been clearly demonstrated. There
is therefore much interest in the use of HPV testing to improve
both the effectiveness and cost-effectiveness of cervical screening.
Thus, it is timely to consider the role of human papilloma virus
(HPV) testing within the cervical screening programme and to
review research into its potential implementation.
METHODS
Eight databases were searched, producing a total of about 2100
papers. Additional references were sought by scanning the citations
of review articles and books devoted to HPV. Ongoing and unpub-
lished studies were identified, but their results are not included.
The main objectives of the review were as follows.
1. To evaluate the available data concerning the role of HPV
testing:
a. in primary screening, either alone or as an adjunct to
cytology;
b. to improve the management of women with low-grade
cytologic abnormalities;
c. to improve the accuracy of follow-up after treatment of
preinvasive or early invasive lesions.
2. To review the methods available for HPV testing and deter-
mine their appropriateness for widespread implementation.
3. To determine what future research is required to obtain more
reliable answers about its use in screening.
An attempt was made to answer a series of questions formulated at
the outset.
Papers were divided into broad categories and initially screened
by title and abstract using predefined criteria. Complete copies of
papers not rejected were obtained, and data were abstracted.
Abstractions were done by one author and checked by another.
Tabular, graphical and textual methods were used to synthesize the
data.
In addition, results from important subsequent publications
have also been noted.
RESULTS
Testing methodology
A range of approaches have been used to detect HPV in smear
material with widely differing results. The most thoroughly
studied methods are now being superseded by newer methods that
offer better sensitivity, specificity and reproducibility and are
easier to perform. However, many of the most relevant studies are
just beginning to reach the literature, and most of the large studies
related to screening are still ongoing with at most only preliminary
reports available. Currently, two consensus primer PCR systems –
the MY09/11 and the GP5+/6+ pairs – and the second-generation
Hybrid Capture system (HC-II) with high risk probes would seem
to be the methods of choice (Manos et al, 1989; de Roda Husman
et al, 1995; Peyton et al, 1998). These three methods all have high
absolute sensitivity for detecting oncogenic viruses and have the
potential for automation. Developments in the form of second-
stage assays may help improve specificity without substantially
reducing sensitivity.
Natural history
HPV is a sexually transmitted disease with peak prevalence in the
age group 20–24 years which gradually declines up to about age
40–45 years, but then may begin to increase slowly again (Herrero
et al, 2000). Most infections are transient, with a median duration
of at most 12 months, and pose no risk of cervical neoplasia: only
the 10–20% that remain persistent are of concern (Ho et al, 1995;
Remmink et al, 1995; Nobbenhuis et al, 1999). Evidence of infec-
tion, either by serology in stored blood samples or by viral DNA in
fixed archival specimens, is found many years before serious
disease is present, and indicates that infection precedes disease
(Walboomers et al, 1995; Lehtinen et al, 1996; Dillner et al, 1997).
Detection of HPV DNA in the absence of cytological abnormali-
ties can also indicate presence of high-grade cervical intraepithe-
lial neoplasia (CIN) which was missed by cytology (Cuzick et al,
1995). Women with minor cytological abnormalities who test
negative for oncogenic HPV have a low risk of developing high-
grade CIN within 3 years. Little is known about the progressive
potential of CIN detected by HPV testing, but missed by cytology
or vice versa.
Prevalence
The review was limited to studies using consensus PCR or Hybrid
Capture, as other tests are much less reliable and give results that
are not comparable. With modern tests, over 95% of all cancers are
HPV positive (Bosch et al, 1995; Walboomers et al, 1999; Cuzick
et al, 2000) and 75–95% of high-grade CIN lesions are associated
with a positive HPV test on exfoliated cells (de Roda Husman et
al, 1995; Herrington et al, 1995; Burger et al, 1996; Clavel et al,
1999; Cuzick et al, 1999). These and other comparative studies
have shown that HPV testing has a greater sensitivity for CIN
II/III than cytology. However, greater variability in the HPV posi-
tivity rate in ‘normal’ populations is seen, leading to concern about
specificity especially in younger women. This variability reflects a
number of factors, including age, extent of sexual exposure,
previous disease, and type of assay used. Overall the positivity rate
of tests for high-risk HPV types in women not known to have CIN
was 13% ranging from 10% for PCR using GP5/6 primers (de
Roda Husman et al, 1995; Kruger-Kjaer et al, 1998) to 20% using
Hybrid Capture II (Clavel et al, 1999; Cuzick et al, 1999; Hill et al,
1999). Rates are about half these levels in women aged over 35
years. The rates for HPV type 16 (the most common oncogenic
type) are much lower but, if only this type was used the sensitivity
for high-grade CIN would be substantially reduced. However,
judicious selection of a few HPV types might improve specificity
without substantially affecting sensitivity.
Modelling
A number of possibilities exist for introducing HPV testing at
different ages and at different screening intervals. It could be used
as the sole primary screening modality, as an adjunct to cytology,
or in the triage of borderline and mild dyskaryosis. Published
modelling studies are limited by the estimates of effectiveness,
which are only now becoming available, and the cost of the test,
which is still not known for high-volume applications. New
modelling studies are presented based on the MISCAN micro-
simulation programme (Habbema et al, 1984), using costs based
on the British programme, and disease models based on the natural
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baseline calculations could be performed. These were sufficient to
show that current knowledge is inadequate for assessing cost-
effectiveness. The results of the modelling work show that for
plausible values of prevalence, screening sensitivities and progres-
sion, HPV testing may be effective and cost-effective. For plau-
sible assumptions about the model parameters, there are uses of
HPV testing that would provide benefits at a lower cost than many
existing healthcare programmes. However, the wide range of
results that come from using high and low estimates for these para-
meters show that more data are needed to refine modelling using
more accurate estimates of key parameters.
Economic and social issues
A range of economic issues related to introducing HPV screening
were surveyed as well as the very sparse literature on psychosocial
aspects. In neither case is the database adequate to draw firm
conclusions.
CONCLUSIONS, IMPLICATIONS AND
RECOMMENDATIONS
Ten conclusions were made in the report and each of these led to
one or more recommendations, the latter being given in italics
below.
1. The clearest role for HPV testing at the moment is in the
management of women with borderline or mildly dyskaryotic
smears (Kjellberg et al, 1998; Manos et al, 1999; Nobbenhuis
et al, 1999; Solomon et al, submitted). In particular those aged
over 30 who test positive for high-risk types could be referred
immediately for colposcopy, while those younger than 30
years who test negative could receive less-intensive surveil-
lance.
The evidence would support limited introduction with careful
monitoring in this context. This should be done in such a way
that comparisons with conventional management could be
made.
a.  The safety of returning women with borderline/mild
smears which are HPV negative to routine screening
requires further research.
b.  HPV testing could either be performed on material
stored from the initial scrape or by inviting women back
for collection of a second sample. If a second sample is
used it could either be taken shortly after the initial
cytology result becomes available or at 6 months. The cost
and psychological implications of these three alternatives
requires careful evaluation.
2. HPV testing with a consensus PCR method or Hybrid Capture
II has a high sensitivity for high-grade CIN, usually exceeding
that of cytology and certainly identifying cases missed by
cytology.
Although this is not sufficient to recommend routine screening
with HPV tests (see below), the evidence would appear to
support limited use of the test in conjunction with cytology in
certain situations (such as when women are likely not to return
for further screening) where high sensitivity is important.
Studies should be carried out to examine the safety of
extending the screening interval and/or stopping screening
after a certain age (e.g. 50 years) in women with history of
negative results for both HPV and cytology.
3. HPV testing appears to be less specific than cytology (as used
for referral in the UK screening programme) with false-posi-
tive rates ranging from 3–10% in ‘normal’ women aged over
35 years: false-positive rates are higher in younger women. It
should be noted that, if borderline smears are considered posi-
tive, the specificity of cytology is also poor particularly in
younger women.
Further work is needed to clarify the management of HPV-
positive but cytology-negative women and/or to establish
methods for determining persistence of HPV infection.
4. The potential exists for HPV testing using one of the newer
assays to become the sole method of primary screening, espe-
cially for older women, but this will require consistent
evidence of high sensitivity for high-grade lesions that are
likely to progress to cancer. For younger women, cytology
may only need to be performed in HPV-positive women. The
cost-effectiveness of such an approach will depend largely on
the relative cost of cytology and HPV testing and the screening
interval employed.
More studies are needed.
5. A full evaluation of HPV testing should provide information
on the length of protection of a negative result and ideally
demonstrate a reduction in cancer incidence. Several trials of
current HPV tests in the 10 000 patient range are ongoing and
should resolve issues of sensitivity, specificity and repro-
ducibility and shed some light on the long-term risk of high-
grade CIN following a negative HPV test.
a.  New studies should take into account these ongoing
trials.
b.  All large ongoing and future studies of HPV testing
should follow women for at least 5 years.
c.  Ongoing studies should be encouraged to collaborate
internationally to maximize the accuracy with which inci-
dence reduction can be estimated.
d.  Consideration should be given to a very large 
(100 000–200 000 participants to receive HPV testing)
randomized clinical trial to evaluate the effect of HPV
testing on cancer incidence, and the length of protection
afforded by a negative HPV test in conjunction with nega-
tive cytology. This should be incorporated into the national
screening programme to minimize costs.
6. A role may exist for HPV testing in post-treatment surveil-
lance of high-grade CIN and localized cancer to determine
more quickly and accurately if treatment has completely eradi-
cated local disease. It may be possible to return women to
routine surveillance if they become HPV-negative one year
after treatment.
Focused trials in the area are needed.
7. Modelling studies show that HPV testing may be a cost-effec-
tive screening modality either alone or in conjunction with
cytology. These models are dependent on the input parameters,
which are currently ill determined due to lack of data.
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HPV screening, it should not yet be implemented in routine
primary screening. Further field studies are needed to improve
estimates of the key model parameters.
8. HPV testing has the potential to be used on self-collected
cervical samples. This could help to improve coverage by
reaching those who do not participate in the current screening
programme (Wright et al, 2000).
a.  The sensitivity of self-sampling requires further evalua-
tion in settings appropriate to the NHS.
b.  Pilot work should investigate whether the option of self-
sampling could improve coverage.
9. HPV testing with Hybrid Capture appears to be a readily
automatable procedure that can achieve high throughput with a
low level of technical support. PCR methods using the
MY09/11 or GP5+/6+ consensus primers provide good results,
but are not yet commercially available.
More work is needed to evaluate the implementation of these
assays in different laboratories.
10.HPV testing needs to be viewed in the context of potential
improvements in cytology using thin-layer preparations taken
from liquid samples and automated reading.
A large study should evaluate the best way of integrating these
technologies and the most cost-effective strategy.
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